Passa al contenuto
Merck
Tutte le immagini(3)

Documenti fondamentali

SAB4100064

Sigma-Aldrich

Monoclonal Anti-IDH1 antibody produced in mouse

clone IDH1-A36, culture supernatant

Sinonimo/i:

Anti-IDH, Anti-IDP, Anti-IDPC, Anti-Isocitrate dehydrogenase 1 (NADP+), soluble (IDH1), Anti-NADP+-specific ICDH, Anti-NADP-dependent isocitrate dehydrogenase, cytosolic, Anti-NADP-dependent isocitrate dehydrogenase, peroxisomal, Anti-Oxalosuccinate decarboxylase, Anti-PICD

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(3)

About This Item

Codice UNSPSC:
12352203
NACRES:
NA.41

Origine biologica

mouse

Coniugato

unconjugated

Forma dell’anticorpo

culture supernatant

Tipo di anticorpo

primary antibodies

Clone

IDH1-A36, monoclonal

Stato

aqueous solution

PM

antigen predicted mol wt 46.7 kDa

Reattività contro le specie

human

tecniche

western blot: suitable

Isotipo

IgG1

N° accesso UniProt

O75874

Condizioni di spedizione

dry ice

Temperatura di conservazione

−20°C

modifica post-traduzionali bersaglio

unmodified

Informazioni sul gene

human ... IDH1(3417)

Descrizione generale

Isocitrate dehydrogenase 1 (IDH1) is encoded by the gene mapped to human chromosome 2q34. It is a member of the isocitrate dehydrogenase enzymes family. IDH1 is mainly found in cytoplasm and peroxisomes.

Immunogeno

IDH1 purified recombinant protein

Azioni biochim/fisiol

Isocitrate dehydrogenase 1 (IDH1) acts as a regulator of cytoplasmic and peroxisomal lipid metabolism in various tissues. It catalyzes the conversion of isocitrate to α-ketoglutarate, which is a key cofactor for 2-OG-dependent dioxygenases. IDH1 facilitates various cellular processes such as adaptation to hypoxia, histone demethylation and DNA modification. It is also involved in the synthesis of plasmalogen lipids in peroxisomes. Somatic mutation of the gene is associated with the development of gliomas and acute myeloid leukaemia (AML).

Stato fisico

Solution in Dulbecco′s Modified Eagle′s Medium with 10% fetal calf serum and 15 mM sodium azide.

Esclusione di responsabilità

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Codice della classe di stoccaggio

10 - Combustible liquids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
066M4825V
051M2777

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
Amary MF, et al.
The Journal of Pathology, 224(3), 334-343 (2011)
IDH1/2 mutation detection in gliomas
Arita H, et al.
Brain Tumor Pathology, 32(2), 79-89 (2015)
IDH1, lipid metabolism and cancer: Shedding new light on old ideas
Bogdanovic E
Biochim. Biophys. Acta Gen. Subj., 1850(9), 1781-1785 (2015)
Julie-Aurore Losman et al.
Science (New York, N.Y.), 339(6127), 1621-1625 (2013-02-09)
Mutations in IDH1 and IDH2, the genes coding for isocitrate dehydrogenases 1 and 2, are common in several human cancers, including leukemias, and result in overproduction of the (R)-enantiomer of 2-hydroxyglutarate [(R)-2HG]. Elucidation of the role of IDH mutations and
M Udugama et al.
Nature communications, 12(1), 2584-2584 (2021-05-12)
Alternative Lengthening of Telomeres (ALT) is a telomere maintenance pathway utilised in 15% of cancers. ALT cancers are strongly associated with inactivating mutations in ATRX; yet loss of ATRX alone is insufficient to trigger ALT, suggesting that additional cooperating factors

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.